US WorldMeds completed the acquisition of four cell therapy assets from Adaptimmune for $55m.

US WorldMeds, a pharmaceutical company, completed the acquisition of four cell therapy assets from Adaptimmune, a biopharmaceutical company that develops T cell therapies against cancer, for $55m. "We were the first company to obtain a marketing authorization for an engineered TCR T-cell therapy, TECELRA, and we have a second cell therapy, lete-cel, with approval anticipated in 2026. However, given the financial situation of the Company, it is clear that securing the right strategic option was critical to maximize value for all of our stakeholders and importantly ensure our patients continue to receive TECELRA. After an extensive review of all strategic alternatives available to Adaptimmune we are convinced that this transaction represents the best path forward for Adaptimmune, our patients and stakeholders," Adrian Rawcliffe, Adaptimmune CEO.